BOSULIF

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Spain, Turkey, UK.

Active ingredients

The drug BOSULIF contains one active pharmaceutical ingredient (API):

1	Bosutinib UNII 844ZJE6I55 - BOSUTINIB MONOHYDRATE
	Bosutinib belongs to a pharmacological class of medicinal products known as kinase inhibitors. Bosutinib inhibits the abnormal BCR-ABL kinase that promotes CML. Modeling studies indicate that bosutinib binds the kinase domain of BCR-ABL. Bosutinib is also an inhibitor of Src family kinases including Src, Lyn and Hck. Bosutinib minimally inhibits platelet-derived growth factor (PDGF) receptor and c-Kit. In in vitro studies, bosutinib inhibits proliferation and survival of established CML cell lines, Ph+ ALL cell lines, and patient-derived primary primitive CML cells.
	Read more about Bosutinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BOSULIF Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EA04	Bosutinib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EA BCR-ABL tyrosine kinase inhibitors
Discover more medicines within L01EA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02419149, 02419157
EE	Ravimiamet	1612055, 1612066, 1612077, 1612088, 1665468, 1773121, 1773132
ES	Centro de información online de medicamentos de la AEMPS	113818001, 113818003, 113818006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	479904, 492377, 558417
FR	Base de données publique des médicaments	60462965, 61669899, 63150294
GB	Medicines & Healthcare Products Regulatory Agency	226977, 226980, 355976
IE	Health Products Regulatory Authority	88032, 88107
IL	מִשְׂרַד הַבְּרִיאוּת	7661, 7662, 8714
JP	医薬品医療機器総合機構	4291036F1028
LT	Valstybinė vaistų kontrolės tarnyba	1069897, 1069898, 1069899, 1069900, 1074112, 1088046, 1088047
NL	Z-Index G-Standaard, PRK	106070, 106089, 151041
PL	Rejestru Produktów Leczniczych	100297089, 100297095, 100417145
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64815001, W64816001, W67871001
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308097446, 8681308097453, 8681308097613, 8681308097620, 8681308097637
US	FDA, National Drug Code	0069-0135, 0069-0136, 0069-0193, 63539-117